公司資料
HCW Biologics 股價、新聞與催化劑
- 股票代碼:
- HCWB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.52 USD (-5.97%)
收盤價
最後更新: 2026年8月17日
12.8M USD
市值
股價為何變動
Following the latest company update, “HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results”, HCWB closed down 8.38% at $2.68 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
公司概覽
Fusion Immunotherapeutics
HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune disease, cancer, and conditions associated with chronic inflammation and cellular senescence. Its pipeline is built around engineered cytokine and multispecific immune-cell engagement technologies.
HCW9302 Treg Program
HCW9302 is an IL-2-based fusion molecule designed to engage CD25 and expand regulatory T cells. The candidate is in a Phase 1 monotherapy study in alopecia areata, with the company evaluating its ability to restore immune balance without broadly suppressing immune function.
HCW11-018b T-Cell Engager
HCW11-018b is a tetravalent T-cell engager generated from the company's proprietary TRBC platform. It is designed to direct CD3-positive effector T cells toward tissue factor-expressing solid tumors while countering immunosuppressive features of the tumor microenvironment.
Cell-Therapy Manufacturing Reagents
HCW9206 is a commercial-ready reagent intended for use in CAR-T cell manufacturing. The program is designed to promote memory stem-cell characteristics that may improve cell persistence and function while supporting more efficient manufacturing processes.
未來催化劑
- Full Phase 1 data for HCW9302 in alopecia areata in Q4 2026.
- Initiation of a clinical trial of HCW11-018b in solid tumors in the first half of 2027, subject to FDA authorization.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。